
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
16 November 2021
Charities call on NHS to treat blood cancer equally in decision-making
The Blood Cancer Alliance undertook an evidence review to inform a new report exploring the unmet needs of people with blood cancer across the UK.
3 February 2022
Leukaemia UK awarded Christmas Grant to support life-saving research
Leukaemia UK are delighted to have been awarded a special Christmas Grant from Kusuma Trust UK.
27 August 2020
Leukaemia UK appoints new CEO
The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, starting her role on 9th September 2020.
15 June 2018
Nick Boles’ Ambulatory Care Unit opening speech
An edited extract of the speech Nick Boles MP made at the official opening of the Leukaemia UK Ambulatory Care Unit.